Publications by authors named "D A Wacker"
Article Synopsis
- Senescent immune cells, which have altered gene expression and resist apoptosis, are linked to worsened outcomes in sepsis among aged individuals, prompting research into the senolytic drug fisetin as a potential treatment.
- A phase 2 clinical trial is underway, involving 220 elderly sepsis patients who will receive either fisetin or a placebo to evaluate fisetin's ability to prevent clinical deterioration and its impact on senescent immune cells.
- Results from this trial will help shape future larger studies and contribute to understanding the role of fisetin in treating sepsis in elderly patients.
Author Correction: Development of a proteomic signature associated with severe disease for patients with COVID-19 using data from 5 multicenter, randomized, controlled, and prospective studies.
Sandra Castro-Pearson Sarah Samorodnitsky Kaifeng Yang Sahar Lotfi-Emran Nicholas E Ingraham David Wacker
Sci Rep
July 2024
Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorders. These compounds are thought to mediate their hallucinogenic and therapeutic effects through the serotonin (5-hydroxytryptamine (5-HT)) receptor 5-HT (ref. ).
View Article and Find Full Text PDFSerotonin [5-hydroxytryptamine (5-HT)] acts via 13 different receptors in humans. Of these receptor subtypes, all but 5-HTR have confirmed roles in native tissue and are validated drug targets. Despite 5-HTR's therapeutic potential and plausible druggability, the mechanisms of its activation remain elusive.
View Article and Find Full Text PDF